You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

224 Results
Scientist, Surveillance Research, Acute and Hospital-Based Care, Ontario Health todd.norwood@ontariohealth.ca  
Chercheur, Recherche en matière de surveillance, Soins aigus et hospitaliers, Santé Ontario todd.norwood@ontariohealth.ca  
Drug
Other Name(s): Imjudo®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Drug
Other Name(s): Herceptin® , Kanjinti™; Ogivri™; Trazimera™; Herzuma®; Ontruzant®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2024
Drug
Other Name(s): Tecvayli®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2025
Document
New
Jan 2025
Guidelines and Advice
Status: Current
ID: MOTAC-7
Updated
Jan 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
oxaliplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Drug
Other Name(s): Trecondyv®
Quick Link(s):
Drug Monograph
Jan 2025
Drug
Other Name(s): Tukysa™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025

Pages